Abstract
5-Substituted uracils were reported to be important core structure of diverse therapeutics. Herein, novel mixed ligand transition metal (Mn, Cu, Ni) complexes of 5-iodouracil (5Iu) with 8-hydroxyquinoline or 8HQ (1-3) and 5- nitrouracil (5Nu) with 8HQ (4-6) have been synthesized. The metal complexes 1-6 exert significant cytotoxicity against HepG2, A-549, HuCCA-1 and MOLT-3 cell lines. Particularly, the cytotoxicities of tested complexes against HepG2 cells show their IC50 values lower than the reference drug. Cu complex of 5Nu (5Nu-Cu-8HQ, 5) is the most potent and promising cytotoxic compound. Mn complex of 5Iu (5Iu-Mn-8HQ, 1) is shown to be the most potent antioxidant. This finding reveals the application of using simple and commercially available bioactive ligands like 5Iu, 5Nu and 8HQ for the design and construction of new lead compounds with significant and promising bioactivities.
Keywords: 5-iodouracil, 5-nitrouracil, Metal complex, SOD and cytotoxic activities, Uracil Derivatives, anticancer drug, antioxidant activity, Melting points, Gibco and Hyclone laboratories, 8HQ, olefinic electron donor, Cytotoxic Activity, Superoxide Dismutase, Antioxidative Activity
Letters in Drug Design & Discovery
Title: Metal Complexes of Uracil Derivatives with Cytotoxicity and Superoxide Scavenging Activity
Volume: 9 Issue: 3
Author(s): Supaluk Prachayasittikul, Apilak Worachartcheewan, Ratchanok Pingaew, Thummaruk Suksrichavalit, Chartchalerm Isarankura-Na-Ayudhya, Somsak Ruchirawat and Virapong Prachayasittikul
Affiliation:
Keywords: 5-iodouracil, 5-nitrouracil, Metal complex, SOD and cytotoxic activities, Uracil Derivatives, anticancer drug, antioxidant activity, Melting points, Gibco and Hyclone laboratories, 8HQ, olefinic electron donor, Cytotoxic Activity, Superoxide Dismutase, Antioxidative Activity
Abstract: 5-Substituted uracils were reported to be important core structure of diverse therapeutics. Herein, novel mixed ligand transition metal (Mn, Cu, Ni) complexes of 5-iodouracil (5Iu) with 8-hydroxyquinoline or 8HQ (1-3) and 5- nitrouracil (5Nu) with 8HQ (4-6) have been synthesized. The metal complexes 1-6 exert significant cytotoxicity against HepG2, A-549, HuCCA-1 and MOLT-3 cell lines. Particularly, the cytotoxicities of tested complexes against HepG2 cells show their IC50 values lower than the reference drug. Cu complex of 5Nu (5Nu-Cu-8HQ, 5) is the most potent and promising cytotoxic compound. Mn complex of 5Iu (5Iu-Mn-8HQ, 1) is shown to be the most potent antioxidant. This finding reveals the application of using simple and commercially available bioactive ligands like 5Iu, 5Nu and 8HQ for the design and construction of new lead compounds with significant and promising bioactivities.
Export Options
About this article
Cite this article as:
Prachayasittikul Supaluk, Worachartcheewan Apilak, Pingaew Ratchanok, Suksrichavalit Thummaruk, Isarankura-Na-Ayudhya Chartchalerm, Ruchirawat Somsak and Prachayasittikul Virapong, Metal Complexes of Uracil Derivatives with Cytotoxicity and Superoxide Scavenging Activity, Letters in Drug Design & Discovery 2012; 9 (3) . https://dx.doi.org/10.2174/157018012799129918
DOI https://dx.doi.org/10.2174/157018012799129918 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Bortezomib in the Treatment of Cancer
Recent Patents on Anti-Cancer Drug Discovery Cytochrome P450-Activated Prodrugs: Targeted Drug Delivery
Current Medicinal Chemistry Therapeutic Strategies for Targeting BRAF in Human Cancer
Reviews on Recent Clinical Trials Chemical Modifications of Synthetic RNAi Agents and in vivo Delivery Techniques
Current Bioactive Compounds High-Throughput Miniaturized Immunoassay for Human Interleukin-6 Using Electrochemical Sandwich-Type Enzyme Immunosensors
Current Pharmaceutical Analysis Anti-HIV Factors: Targeting Each Step of HIV’s Replication Cycle
Current HIV Research Dual Energy CT for Monitoring Targeted Therapies in Patients with Advanced Gastrointestinal Stromal Tumor: Initial Results
Current Pharmaceutical Biotechnology Protein-Protein Interaction Inhibitors: Small Molecules from Screening Techniques
Current Topics in Medicinal Chemistry Therapeutic Use of Chemokines
Current Pharmaceutical Design Therapeutic and Diagnostic Applications of Nanoparticles
Current Drug Targets <i>In Silico</i> Approach to Predict the SARS-COV2 Derived Candidate MiRNAs as a Potential Antiviral Therapy
Current Drug Therapy Targeting the Wingless Signaling Pathway with Natural Compounds as Chemopreventive or Chemotherapeutic Agents
Current Pharmaceutical Biotechnology Long Noncoding RNA MALAT1: Insights into its Biogenesis and Implications in Human Disease
Current Pharmaceutical Design Meet Our Editorial Board Member
Letters in Drug Design & Discovery The PKB/AKT Pathway in Cancer
Current Pharmaceutical Design Antioxidant Therapy for the Treatment of Oxidative Stress Associated to Cancer and Cancer- Related Anorexia/Cachexia
Current Nutrition & Food Science Antiproliferative Activity of Cobra Venom Cytotoxins
Current Topics in Medicinal Chemistry The Future of Collateral Artery Research
Current Cardiology Reviews Effect of Liposomes with Different Double Arms Polyethyleneglycol on Hepatic Metastasis Model Mice and Evaluation Using a Fluorescent Imaging Device
Current Drug Delivery Kidney Diseases and Chemokines
Current Drug Targets